Synthesis and Characterization of ZIF-90 Nanoparticles as Potential Brain Cancer Therapy

Human glioblastoma is probably the most malignant and aggressive among cerebral tumors, of which it represents approximately 80% of the reported cases, with an overall survival rate that is quite low. Current therapies include surgery, chemotherapy, and radiotherapy, with associated consistent side...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 16; no. 3; p. 414
Main Authors Monarca, Lorenzo, Ragonese, Francesco, Sabbatini, Paola, Caglioti, Concetta, Stamegna, Matteo, Palazzetti, Federico, Sportoletti, Paolo, Costantino, Ferdinando, Fioretti, Bernard
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.03.2024
MDPI
Subjects
Antimitotic agents
Antineoplastic agents
B cells
Bioavailability
Biocompatibility
Brain cancer
Cancer
Cancer therapies
Cannabidiol
Chemical properties
Chemotherapy
drug targeting
glioblastoma
Gliomas
Health aspects
Kinases
Medical prognosis
MOF
Mutation
Nanoparticles
Penicillin G
Proteins
Tumor necrosis factor-TNF
Tumors
U251
ZIF-90
Zinc
United States > US
drug targeting
glioblastoma
nanoparticles
ZIF-90
MOF
U251
berberine
Online AccessGet full text

Cover

More Information
Summary:Human glioblastoma is probably the most malignant and aggressive among cerebral tumors, of which it represents approximately 80% of the reported cases, with an overall survival rate that is quite low. Current therapies include surgery, chemotherapy, and radiotherapy, with associated consistent side effects and low efficacy. The hardness in reaching the site of action, and overcoming the blood-brain barrier, is a major limitation of pharmacological treatments. In this paper, we report the synthesis and characterization of ZIF-90 (ZIF, Zeolitic Imidazolate Framework) nanoparticles as putative carriers of anticancer drugs to the brain. In particular, we successfully evaluated the biocompatibility of these nanoparticles, their stability in body fluids, and their ability to uptake in U251 human glioblastoma cell lines. Furthermore, we managed to synthesize ZIF-90 particles loaded with berberine, an alkaloid reported as a possible effective adjuvant in the treatment of glioblastoma. These findings could suggest ZIF-90 as a possible new strategy for brain cancer therapy and to study the physiological processes present in the central nervous system.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics16030414